BioCentury | Oct 16, 2014
Strategy

New CAR shopping

...CTAG1B )] T cell receptor, the MAGE [melanoma-associated antigen] T cell receptor, the SSX2 [ synovial sarcoma X breakpoint 2...
BioCentury | Jun 9, 2014
Company News

Kite Pharma Inc., National Institutes of Health deal

...acquired an exclusive, worldwide license from NIH to IP related to a TCR-based therapy targeting synovial sarcoma X breakpoint 2 (SSX2)...
Items per page:
1 - 2 of 2